How to Buy Adaptimmune Therapeutics Stock
Adaptimmune Therapeutics PLC
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom.
Adaptimmune Therapeutics stock last closed at $0.26, down 5.05% from the previous day, and has decreased 77.13% in one year. It has overperformed other stocks in the Biotechnology industry by 0 percentage points. Adaptimmune Therapeutics stock is currently +34.87% from its 52-week low of $0.20, and -82.23% from its 52-week high of $1.48.
As of Apr 29, 2025, there are 1.54B ADAP shares outstanding. The market capitalization of ADAP is $67.79M. In the last 24 hours, 551,810 ADAP shares were traded.
How to Buy Adaptimmune Therapeutics Stock
Not sure how to invest in Adaptimmune Therapeutics stock? Here's how.
- Decide where to buy Adaptimmune Therapeutics stock: You need to pick an online brokerage, but don't worry - we've researched dozens of stock brokerages and apps to help you determine where to buy Adaptimmune Therapeutics stock.
- Open your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've identified.
- Fund your investment account: Choose your payment method and add your info.
- Research Adaptimmune Therapeutics stock: The Adaptimmune Therapeutics ticker symbol is ADAP. Is Adaptimmune Therapeutics stock a good investment? Should you buy shares of ADAP? How do ADAP's underlying business fundamentals look? Do top analysts think Adaptimmune Therapeutics is a good buy? Why has ADAP's stock price moved recently? (Hint: Our stock analysis website can help you evaluate if ADAP is a good stock to buy).
- Make your ADAP trade: Decide if you will purchase ADAP shares at the current market price or use a limit order to buy ADAP shares at a specific price.
- Track your ADAP position: Create a watchlist to watch your new investment in Adaptimmune Therapeutics stock.
Step 1: Decide where to buy Adaptimmune Therapeutics stock
You need a brokerage account to access the NASDAQ market and buy ADAP stock.
Our favorite brokerage: eToro
Based on our research, eToro is the best brokerage. eToro gives you:
- Invest in stocks with zero commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still invest in the stock.
- Access to world markets: From Tech to Industrials, New York to Tokyo (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's leading stock exchanges.
- Social investing: eToro boasts a community with more than 20 million users around the world. Talk to, learn from, and copy the crypto trades of other investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other financial assets: Such as ETFs and cryptos.
Get $10 towards your purchase of shares by opening an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Open your brokerage account
Now that you've picked the right brokerage, the next step is to fill out some personal information so you can invest in ADAP stock today.
How to Open a New Investment Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Provide your personal info to open your new brokerage account.
- Submit your application by clicking the "Create Account" button. Get started with eToro today
Step 3: Fund your investment account
Now that you've finished signing up on the best stock market app for beginners, you can securely and quickly fund your account:
Check out the walkthrough below to see the process of depositing funds into your new investment account.
Step 4: Research Adaptimmune Therapeutics stock
After you have decided on the best place to buy Adaptimmune Therapeutics stock, it's crucial to analyze their stock prior to investing, so you truly comprehend the risk and upside.
Adaptimmune Therapeutics Numbers
Adaptimmune Therapeutics Fundamentals
WallStreetZen was designed to help everyday investors perform better fundamental analysis.
You can see all of the due diligence checks on ADAP's stock page.
Is ADAP stock overvalued?
Analysts use a variety of different financial metrics, analyses, models, and charts to gauge ADAP's true value.
Using relative valuations ratios:
- ADAP could be overvalued based on its P/B ratio of 5.72x, relative to Biotechnology industry P/B ratio of 4.37x
You can do more valuation analysis on ADAP's stock here.
How do ADAP Financials look?
Signs that ADAP is financially healthy:
- ADAP has cash burn of 74092000. It has sufficient cash and short-term investments to cover this for at least one year.
- ADAP has $153.67M in cash and short term investments. This is sufficient to cover its annual cash burn of $74.09M.
- There are more short-term assets than long-term liabilities on the ADAP balance sheet.
- There are more short-term assets than short-term liabilities on the ADAP balance sheet.
Signs that ADAP is not financially healthy:
- ADAP has a relatively high debt to equity ratio of 19.76.
- Total ADAP debt is higher than 5 years ago, relative to shareholder equity.
- ADAP profit margin has gone up by 1.49 percentage points in the past year, but the company is still unprofitable.
Is it a good time to buy Adaptimmune Therapeutics stock, according to Wall Street analysts?
Out of 5 Wall Street analysts who give recommendations on ADAP, the consensus analyst rating on ADAP is a Buy
Please note that analyst forecasts are not recommendations, nor are they investment advice.
You can dig deeper into what analysts are forecasting on the Adaptimmune Therapeutics stock forecast page.
ADAP Technical Indicators
ADAP Revenue
Last year, ADAP revenue was $178.03M. Over the past five year, ADAP's revenue has increased by 175.49% per year. This was faster than the Biotechnology industry average of 45.47%.
You can analyze ADAP's earnings and revenue performance here.
Who is buying/selling ADAP?
Over the last year, insiders at ADAP have sold more shares than they have bought.
William C. Bertrand Jr., Chief Operating Officer of ADAP, was the latest ADAP insider to sell. They sold $3,244.30 worth of ADAP shares on Jan 17, 2025.
Dig into more about who owns ADAP stock here.
Does ADAP stock generate passive income?
No, Adaptimmune Therapeutics doesn't provide an income stream by paying out dividends.
Get analysis from other traders
One of the reasons eToro is our favorite brokerage is because of its social trading community.
Click below to learn what other traders have to say.
Step 5: Make your ADAP trade
There are two main options:
- Market order: A market order is an order to buy or sell a security at the best possible price.
Market orders are usually fine. - Limit order: A limit order enables you to buy or sell a security at a specific price (or better).
If you want to make sure you're buying or selling at an exact dollar amount limit, use a limit order.
Press the Open button and your broker will place the order.
If you require additional help investing in stocks on eToro, click the helpful video below:
Step 6: Track your ADAP position
Now that you own some ADAP stock, you'll want to keep up with your new stock purchase.
Start a watchlist to track your ADAP stock.
ADAP Feed
How to Buy Stock in Adaptimmune Therapeutics
To reiterate, here are the 6 steps you need to take to buy Adaptimmune Therapeutics stock right now:
- Decide where to buy Adaptimmune Therapeutics stock
- Open your brokerage account
- Fund your investment account
- Research Adaptimmune Therapeutics stock
- Make your ADAP trade
- Track your ADAP position
If you require a brokerage account, eToro is our favorite option.
Get Started with eToro TodayIf you want to watch your new investment in Adaptimmune Therapeutics, add ADAP to your watchlist below.
Related "How To" Guides
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.